SUBSCRIBE TO OUR NEWSLETTER →
BECOME A MEMBER

COVID-19

COVID-19 is an infectious disease caused by the SARS-CoV-2 virus that has affected millions of people worldwide. In September 2021, the World Health Organization (WHO) confirmed more than 4.5 million deaths worldwide.

THE CHALLENGE

The emergence of COVID-19 has marked a turning point in research on infectious diseases.

Further research is needed to find treatments that work for the acute disease, prevent is progression and reduce mortality. Likewise, it is estimated that 10% of people who have recovered from this infection are left with persistent COVID: the causes of this syndrome need to be found and patients must be offered the best therapeutic solutions.

WHAT HAVE WE DONE SO FAR?

2020

We have conducted more than 20 clinical trials with international institutions to advance knowledge about the virus.

We started up the first Persistent COVID-19 Unit in Spain.

We launched the #JoEmCorono campaign to help research on SARS-CoV-2, managing to raise 5 million euros.

2022

We began the PAX study, which is the first in Spain that aims to identify a treatment for persistent COVID-19

LINES OF ACTION

Rapid tests

During 2000 and 2021, several studies were carried out to evaluate the rapid tests that already existed on the market as well as newly created ones.

Screening with rapid test

On March 27, 2021, around 5,000 spectators attended a Love of Lesbian concert at the Palau Sant Jordi in Barcelona after undergoing screening with a rapid antigen test and following protocols to prevent the transmission of the virus such as mask wearing. The analysis of the results has allowed us to confirm that the event had no impact on the transmission of COVID-19.

New variants

Currently, the emergence of new variants of the virus and cases of reinfection are two more fields of study for our team, since their detection and knowledge will allow more useful and effective epidemiological control strategies to be established.

Persistent COVID-19

We promote the first Persistent COVID-19 Unit in Spain.

LATEST NEWS

FEATURED PROJECTS

HIPRA RBDCOV

Identify a vaccine for immunocompromised patients

Within the framework of the European RBDCOV project led by HIPRA and made up of hospitals, research centres and entities from different European countries, the vaccine is being studied as a booster dose for immunocompromised people and, shortly, studies will also begin in children and adolescents under the age of 16.

PAX Study

Identify a treatment for persistent COVID-19

One of the most plausible causes of this syndrome is that after acute infection with SARS-CoV-2, inflammatory substances remain in the blood and are responsible for persistent symptoms. This study proposes a plasma replacement for patients suffering from persistent COVID-19 symptoms.

CaixaResearch grant for Health Research 2022

Identify which are the key affected genes involved in persistent COVID-19

One in 10 people who get COVID-19 continue to suffer from symptoms months after infection. This project aims to decipher the role of epigenetics in persistent COVID-19, assessing whether there are alterations at this level and, at the same time, identifying possible neurological and immune system alterations.

MEET THE TEAM OF THIS AREA OF KNOWLEDGE

Lourdes Mateu

Head of COVID-19 Section – Doctor and Researcher

Gemma Lladós

Doctor and Researcher

Cristina López

Doctor and Researcher

Cora Loste

Doctor and Researcher

José Ramon Santos

Doctor and Researcher

Oriol Mitjà

Head of Community infection control strategies

Clara Suñer

Postdoctoral Researcher

Andrea Alemany

Doctor and Researcher

Camila González

Postdoctoral Researcher

Miquel Àngel Rodríguez

Project Manager

Laia Bertran

Knowledge translation coordinator

Sergi Gavilán

Project Assistant

HELP US FIGHT THIS AND OTHER INFECTIONS!

We need your support to continue conducting independent clinical research with the aim of treating and curing people with an infectious disease.